Primary Job Title President, CEO & Founder Primary Organization 
Engage Therapeutics
Location Summit, New Jersey, United States Regions Greater New York Area, East Coast, Northeastern US Gender Male
LinkedIn View on LinkedIn
Greg, a biopharma leader for more than 20 years, has been personally affected by epilepsy. After years of absence seizures, which often precede epilepsy, his son Conner was diagnosed with epilepsy in 2014. Greg is dedicated to leveraging his drug development experience and working with key opinion leaders (KOLs) to identify new therapeutic options
for patients affected by epilepsy. He, along with his team of KOLs, believe they have finally found that option with Staccato Alprazolam.
Prior to founding Engage Therapeutics, Greg played an integral role in the growth of Advaxis Immunotherapies, a Princeton, N.J., based biotech company developing immuno-oncology therapies for patients with hard-to-treat cancers through its bacterial vector system, Lm Technology™. As its Chief Operating Officer, he was instrumental in helping to secure more than $200 million in funding and in identifying and negotiating partnerships with companies such as Amgen, AstraZeneca and Merck & Co., Inc.
Greg also served as a President of Unigene Laboratories, Inc. As ImClone’s General Counsel, Greg played a key role in managing multiple clinical and regulatory activities that led to the 2008 acquisition by Eli Lilly for $6.5 billion. Earlier in his career, Greg was responsible for providing legal advice to the AstraZeneca oncology franchise as senior counsel and he started his biopharma legal career at the national law firm of Morgan Lewis.
Greg earned his bachelor of science from Syracuse University and his JD from Temple University School of Law.
